If you have ulcerative colitis and your gastroenterologist has prescribed Skyrizi, the honest answer to whether Blue Cross Blue Shield covers it is that it depends on which Blue plan you have. Blue Cross Blue Shield is a federation of more than 30 independent, locally operated companies, and each one writes its own medical policy, formulary, and step-therapy rules. Skyrizi, known generically as risankizumab-rzaa, is a relatively new option for ulcerative colitis. It was approved by the FDA for moderately to severely active ulcerative colitis in adults on June 18, 2024. Because that indication is recent, most Blue plans treat it as a prior-authorization drug, and many require you to try other therapies first. This article explains how that variability works and how to find your own plan's answer.
Why Coverage Varies So Much Across Blue Plans
The single most important thing to understand is that there is no one Blue Cross Blue Shield Skyrizi policy. Anthem in California, Horizon in New Jersey, Blue Cross NC, and Blue Cross Blue Shield of Mississippi are separate companies that set separate rules. Two patients with the same diagnosis and the same drug can get different answers depending on geography, employer plan design, and which pharmacy benefit manager the plan uses, often CarelonRx or Prime Therapeutics. The contrast is real and documented. Blue Cross NC requires a trial of at least one conventional agent such as mesalamine, sulfasalazine, azathioprine, or a corticosteroid for moderate ulcerative colitis before approving Skyrizi. By contrast, Blue Cross Blue Shield of Mississippi lists Skyrizi as a preferred Step 1a agent for ulcerative colitis, meaning it can be used earlier once the patient has failed at least one conventional agent. Do not assume a guaranteed tier, copay, or approval based on what another patient experienced.
Where Skyrizi Tends to Sit in Treatment Sequence
Because the ulcerative colitis indication arrived in 2024, many Blue plans position Skyrizi as a later-line option after one or more earlier biologics. The clinical data help explain why coverage criteria often ask what you have already tried. Skyrizi is an interleukin-23 inhibitor that selectively binds the p19 subunit of IL-23, and its ulcerative colitis approval rests on the INSPIRE induction and COMMAND maintenance phase 3 trials. A post hoc analysis of INSPIRE and COMMAND found that patients who had already failed advanced therapy still benefited, with week 52 clinical remission of 36.6% on the 180 mg dose versus 23.2% on placebo, though remission rates ran lower than in biologic-naive patients. That evidence supports its use even after prior biologic failure, which is exactly the population many Blue step-therapy rules are written around.
How the Benefit Split and Dosing Affect Coverage
Skyrizi for ulcerative colitis is given in two phases, and the phases can be billed under different parts of your insurance. The FDA label specifies 1,200 mg by intravenous infusion at weeks 0, 4, and 8, then 180 mg or 360 mg by subcutaneous injection at week 12 and every 8 weeks thereafter. The intravenous induction phase is frequently processed under the medical benefit, which is why some Blue companies publish a separate provider drug policy for it, such as the Blue Shield of California medical-benefit drug policy for intravenous risankizumab. The subcutaneous maintenance injections often run through the pharmacy benefit and a specialty pharmacy. This split matters because each side can have its own prior authorization, its own cost share, and its own approval timeline, so confirm both before your first infusion.
How to Find Your Own Plan's Rules
Start with the documents your specific Blue company publishes rather than a general search. Log in to your member portal and pull two things: the medical policy or pharmacy coverage policy that names risankizumab or Skyrizi, and the current formulary or drug list that shows its tier and any step-therapy flag. The member services number on the back of your card can also tell you whether Skyrizi is processed under medical or pharmacy and what you must document first.
When you locate the policy, look closely for these items:
Whether a trial and failure of one or more preferred agents is required, and exactly which agents count
Tuberculosis screening and other documentation the plan demands before approval
The benefit under which each phase is covered and the prior authorization deadline
Building a Strong Authorization or Appeal
Most denials for a newer indication come down to missing documentation rather than a flat refusal of the drug. Because Blue plans frequently require proof of prior treatment failures, the strongest thing you and your gastroenterologist can do is assemble a clear record of every ulcerative colitis therapy you have tried, the dose, the duration, and why each was stopped, whether for inadequate response or intolerance. This record maps directly onto the INSPIRE and COMMAND evidence in prior-therapy patients that supports later-line use, which strengthens a medical-necessity letter. If the plan denies the request, you have the right to appeal, and a well-documented prior-failure history plus the FDA-approved indication is the core of that appeal. Coverage of Skyrizi for ulcerative colitis under Blue Cross Blue Shield is rarely automatic, but it is often achievable when your paperwork matches your specific plan's published criteria.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.